Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Hematology and Megakaryopoiesis Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for THPO drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | THPO ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed for native glycosylation. |
View THPO Products |
| Gene Delivery | THPO Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View THPO Products |
| Benchmark Ab | Anti-THPO / Anti-MPL Recombinant Antibody Recombinant positive controls for binding and neutralization assays. |
View THPO Products |
| Validator | THPO siRNA Set For knockdown verification in functional assays. |
View THPO Products |
| Related Target A | MPL (TPO Receptor) The cognate receptor for THPO, critical for signaling validation and agonist screening. |
View MPL Products |
| Related Target B | EPO (Erythropoietin) Parallel hematopoiesis regulator, essential for lineage specificity and cross-reactivity panels. |
View EPO Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native Glycosylation Requirements | HEK293 expressed THPO recombinant proteins preserve native post-translational modifications. |
| Receptor Activation Validation | High-purity human MPL extracellular domain (ECD) proteins for precise binding kinetics. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live THPO R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for THPO therapeutics is intensifying, with major players shifting focus from traditional recombinant proteins to next-generation TPO receptor agonists (TPO-RAs), including small molecules, peptibodies, and agonist monoclonal antibodies. As first-generation therapies reach the clinic, the next wave of R&D is targeting prolonged half-life, reduced immunogenicity, and oral bioavailability to manage thrombocytopenia across oncology, hepatology, and autoimmune indications.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Recombinant Protein / Fusion | 3SBio, Kyowa Kirin | Chemotherapy-Induced Thrombocytopenia (CIT) | Native Glycosylation Validation (Need HEK293-expressed THPO) |
| Peptibody / Agonist Ab | Amgen, Shionogi | Immune Thrombocytopenia (ITP) | MPL Dimerization & Signaling (Need Lentivirus for MPL Stable Cell Lines) |
| Small Molecule TPO-RA | Novartis, Eisai | Chronic Liver Disease (CLD) Thrombocytopenia | Competitive Binding Assay (Need High-Purity MPL & THPO Antigens) |